Slide 1: Combining eftilagimod alpha and pembrolizumab: overall survival data in 1L NSCLC, TACTI-002
Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma cohort of TACTI-002 Phase II study of soluble LAG-3 combined with an anti-PD-1 antibody in 1st line metastatic NSCLC Carcereny E1
Slide 2: Declaration of Interests
DECLARATION OF INTERESTS Enric Carcereny Consultant or Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Roche, Takeda. Speaking: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Pfizer, Roche, Takeda. Grant support: Merck KGaA. Other: Bris
Slide 3: Eftilagimod alpha (efti) & Trial Design
Eftilagimod alpha (efti) & Trial Design • efti: a soluble LAG-3 protein and MHC Class II agonist that leads to a broad anti-cancer immune response, including CD8+ T cell activation & proliferation, through activating antigen presenting cells (APC). • Distinct from anti-LAG-3: efti targets MHC Class
Slide 4: Baseline Disease Characteristics, Exposure & Safety
Baseline Disease Characteristics, Exposure & Safety • 114 patients recruited at 18 sites across 6 countries between Mar 2019-Nov 2021. • Unselected for PD-L1 expression including ~75% of patients with a PD-L1 Tumor Proportion Score (TPS) of <50%. • Median exposure for efti of 24.7 weeks (range: 0.1-
Slide 5: Efficacy - ITT
Efficacy - ITT • Median OS of 20.2 mo in ITT where ~75% of patients had PD-L1 TPS score <50%, including ~35% with PD-L1 TPS of <1%. • 45/114 (39.5%) received 2nd line therapy → mostly chemotherapy-based (42/45; 93.3%). • Median DoR of 21.6 mo in the ITT. 1 according to iRECIST. 2 95% CIs calculated
Slide 6: Efficacy by PD-L1
Efficacy by PD-L11 • Promising efficacy (ORR, PFS, OS, DOR) visible across all PD-L1 subgroups1,2. • For TPS ≥1%, mOS of 35.5 mo, mPFS2 of 11.2 mo, mDOR2 of 24.2 mo. • For TPS ≥50%, mOS not reached despite long median follow up of 25.1 mo. Tumor Response by central PD-L11, N=90 <1%1, 1-49%1, ≥50%1,
Slide 7: Conclusions
Conclusions • Efti plus pembrolizumab lead to promising median overall survival (mOS) in 1st line NSCLC patients with TPS ≥1% (35.5 mo), TPS 1-49% (23.4 mo) and TPS ≥50% (not reached). • Encouraging efficacy seen across response endpoints (ORR, PFS, DoR and OS) and PD-L1 subgroups (<1%, ≥1%, 1-49% a
Slide 8: Acknowledgements
Acknowledgements Thank you to all the participating patients and their families. And thank you to all participating sites: Catalan Institute of Oncology Badalona-Hospital Germans Trias i Pujol, B-ARGO group, Badalona, Spain; Vall d’Hebron University Hospital, Barcelona, Spain; Hospital de la Santa C